A multi-center retrospective study on the efficacy and safety of regorafenib <i>vs.</i> regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma.

Subgroup analysis In the subgroup analysis of patients who had received first-line treatment according to the TKI strategy, the PFS still exhibited a highly significant difference between the two groups (P=0.0018) ( Figure 4 ): the mPFS was 4.0 months (95% CI, 3.6–6.8 months) in the regorafenib group and 10.0 months (95% CI, 7.2–32.4 months) in the combination group.

also in 132,142 other papers